

# About JUVÉDERM® Ultra Plus XC



## Introduction

Before beginning your treatments, please review this important information.

## Glossary of terms

**Aesthetic**—cosmetic, related to beauty

**Anaphylaxis**—severe allergic reaction

**Bovine-based collagen**—a dermal filler created from cow hides

**Complimentary**—free, at no cost

**Cushioning agent**—absorbs shock

**Duration**—length of time

**Expressed a preference**—subjects liked better

**Gram-positive bacterial proteins**—remnants of protein from the bacteria that produce the hyaluronic acid used in JUVÉDERM® Ultra Plus XC

**Hyaluronidase**—an enzyme that breaks down hyaluronic acid

**Hypertrophic scarring**—a thick, hard scar that grows over the injured area

**Inflammatory reaction**—a localized response to injury, typically including pain, heat, redness, and swelling

**Injection-site responses**—side effects from treatment

**Keloid formation**—a thick, hard scar that grows outside the injured area

**Nasolabial folds (NLFs)**—the lines or wrinkles that run from the corners of the nose downward toward the corners of the mouth

**NSAID**—Nonsteroidal anti-inflammatory drug, such as aspirin or ibuprofen

**Optimal**—the best possible outcome

**Pigmentation disorders**—a lightening or darkening of an area of the skin

**Topical**—cream or ointment applied to a certain area of the skin and affecting only the area to which it is applied

## What is it?

JUVÉDERM® Ultra Plus XC injectable gel is a colorless hyaluronic acid gel that contains a small quantity of local anesthetic (lidocaine) and is injected into facial tissue to smooth wrinkles and folds, especially around the nose and mouth. Hyaluronic acid is a naturally occurring sugar found in the human body. The role of hyaluronic acid in the skin is to deliver nutrients, hydrate the skin by holding in water, and to act as a cushioning agent. The role of lidocaine is to reduce the pain associated with injections into the skin.

## What does it do?

JUVÉDERM® Ultra Plus XC temporarily adds volume to facial tissue and restores a smoother appearance to the face. The lidocaine in the gel improves the comfort of the injection.

## How is it used?

JUVÉDERM® Ultra Plus XC is injected into areas of facial tissue where moderate to severe facial wrinkles and folds occur. It temporarily adds volume to the skin and may give the appearance of a smoother surface.

## What will it accomplish?

JUVÉDERM® Ultra Plus XC injectable gel will help to smooth moderate to severe facial wrinkles and folds. Most patients need 1 treatment to achieve optimal wrinkle smoothing, and the results last about 1 year.

## What are possible side effects?

Most side effects are mild or moderate in nature, and their duration is short lasting (7 days or less). The most common side effects include, but are not limited to, temporary injection-site reactions such as: redness, pain/tenderness, firmness, swelling, lumps/bumps, bruising, itching, and discoloration.

As with all skin-injection procedures, there is a risk of infection.

## Are there any reasons why I should not receive JUVÉDERM® Ultra Plus XC (contraindications)?

Your physician will ask about your medical history to determine if you are an appropriate candidate for treatment. The product should not be used in patients who have:

- Severe allergies marked by a history of anaphylaxis or history or presence of multiple severe allergies
- A history of allergies to lidocaine or Gram-positive bacterial proteins

## What should my physician warn me about?

The safety and effectiveness for the treatment of areas other than facial wrinkles and folds (such as lips) have not been established in controlled clinical studies.

## What precautions should my physician advise me about?

The following are important treatment considerations for you to discuss with your physician and understand in order to help avoid unsatisfactory results and complications.

- Patients who are using substances that can prolong bleeding, such as aspirin or ibuprofen, as with any injection, may experience increased bruising or bleeding at injection site. You should inform your physician before treatment if you are using these types of substances
- If laser treatment, chemical peeling, or any other procedure based on active dermal response is considered after treatment with JUVÉDERM® Ultra Plus XC, there is a possible risk of an inflammatory reaction at the treatment site
- JUVÉDERM® Ultra Plus XC injectable gel should be used with caution in patients on immunosuppressive therapy, or therapy used to decrease the body's immune response, as there may be an increased risk of infection
- The safety for use during pregnancy, in breast-feeding females, or in patients under 18 years has not been established
- The safety in patients with a history of excessive scarring (eg, hypertrophic scarring and keloid formations) and pigmentation disorders has not been studied

## What did the clinical study show?

In the primary US clinical study to establish safety and effectiveness, 144 subjects were followed for 24 weeks after injection with JUVÉDERM® Ultra Plus (without lidocaine) in 1 nasolabial fold (NLF) and ZYPLAST® dermal filler (bovine-based collagen) in the other. The percentage of subjects who reported common injection-site responses are presented in the table below.


Injection-Site Responses	JUVÉDERM® Ultra Plus		ZYPLAST®	
	n <sup>b</sup>	%	n <sup>b</sup>	%
Redness	129	90%	128	89%
Pain/tenderness	129	90%	123	85%
Firmness	127	88%	122	85%
Swelling	124	86%	121	84%
Lumps/bumps	120	83%	113	78%
Bruising	87	60%	69	48%
Itching	49	34%	51	35%
Discoloration	49	34%	43	30%

<sup>a</sup> Occurring in > 5% of subjects.

<sup>b</sup> Number of subject NLFs with each specific injection-site response.

Injection-site responses were similar in duration and frequency for the JUVÉDERM® Ultra Plus injectable gel and ZYPLAST® treated sides, were usually mild or moderate in severity, did not require intervention, and lasted 7 days or less.

JUVÉDERM® Ultra Plus was found to provide a more persistent wrinkle correction than ZYPLAST® dermal filler over the 24-week course of the study. The percentage of subjects who maintained improvement with JUVÉDERM® Ultra Plus at 24 weeks was 90% compared to 40% with ZYPLAST®. At the conclusion of the study, 123 (84%) of 146 subjects expressed a preference for JUVÉDERM® Ultra Plus injectable gel, while only 15 (10%) expressed a preference for ZYPLAST®; and 8 (5%) had no preference.




**What did the clinical study show?** (continued)

Subjects who completed the 24-week study were invited to return for a complimentary repeat treatment. Subjects returned at their (or their physician's) convenience. Of the 146 subjects, 111 (76%) returned for repeat treatment, on average at 9 months after their last injection. Forty-seven (47) subjects returned more than 36 weeks (9 months) after their last injection: the percentage of those subjects who had maintained improvement with JUVÉDERM® Ultra Plus was 81%. Of the twenty-three (23) subjects who returned more than 48 weeks (1 year) after their last injection, 78% had maintained improvement.

At multiple time points in the clinical study, subjects' nasolabial folds were rated on a scale from 0 to 4:


Using this 5-point wrinkle assessment scale, the mean improvement since baseline was 2.0 at 2 weeks, 1.5 at 24 weeks, and 1.1 beyond 48 weeks after treatment.

Score	Description
0	None
1	Mild
2	Moderate
3	Severe
4	Extreme




A subset of these subjects enrolled in a second study that followed subjects for 24-48 weeks after repeat treatment. Twenty-four (24) subjects were enrolled in the study. Twenty-three (23) were evaluated at 24 weeks (6 months) after repeat treatment with 91% maintaining improvement. Ten (10) subjects returned for evaluation 48 weeks (1 year) after repeat treatment: the percentage of those subjects who had maintained improvement with JUVÉDERM® Ultra Plus injectable gel was 90%.

The mean improvement since baseline (ie, the average improvement from before treatment in patients using the wrinkle assessment scale listed in Table 2) was 1.7 at 24 weeks and 1.5 at 48 weeks after repeat treatment.



In another clinical study comparing JUVÉDERM® Ultra Plus with and without lidocaine, 36 subjects received the product with lidocaine in 1 nasolabial fold and the product without lidocaine in the other. Subjects rated the level of pain during each injection. Pain was significantly less on the side that received JUVÉDERM® Ultra Plus XC, and in comparing the 2 injections, 33 subjects (92%) found the lidocaine formulation to be less painful.



**What side effects have been reported through voluntary postmarketing surveillance of JUVÉDERM® Ultra Plus (without lidocaine) use in and outside of the United States?**

The most commonly reported serious adverse events were swelling, redness, bruising, and pain.

- Swelling, redness, and pain generally occurred from immediately to 2 months after injection. The treatment prescribed included NSAIDs, antihistamines, antibiotics, steroids, and hyaluronidase. In most cases, these went away within a few days to 5 weeks
- Bruising generally occurred from immediately to one day after injection. Treatment included NSAIDs, antihistamines, antibiotics, steroids, and hyaluronidase. In most cases it went away within a few days to 6 weeks

Additionally there have been reports of nodules, infection, and inflammation.

- Nodules generally occurred from immediately to 2 months after injection. Treatment included NSAIDs, antibiotics, steroids, and hyaluronidase. In most cases, nodules went away within one month
- Infection generally occurred from immediately to one month after injection. Treatment included antibiotics, pain killers, and antibacterial drugs
- Inflammation generally occurred from the day of treatment to one day postinjection. Treatment included antibiotics, steroids, and needle aspiration. Resolution of symptoms has been reported within 4 days

Other events that were reported included: allergic reaction, blister, skin rash, bleeding at the injection site, necrosis at the injection site, abscess at the injection site, and headache.

**Do the injections hurt?**

Some discomfort may occur during and after the injection. JUVÉDERM® Ultra Plus XC injectable gel contains an anesthetic to reduce injection-site pain. Physicians may choose to numb (anesthetize) the treatment area with a cream placed directly on the injection site (topical) to further minimize discomfort.

**What should I expect following the procedure?**

Your physician will tell you what to expect following treatment with JUVÉDERM® Ultra Plus XC. Within the first 24 hours, you should avoid strenuous exercise, extensive sun or heat exposure, and alcoholic beverages. Exposure to any of the above may cause temporary redness, swelling, and/or itching at the injection sites. If there is swelling, you may need to place an ice pack over the swollen area. You should ask your physician when makeup may be applied after your treatment.

**Does the correction last forever?**

No. Correction is temporary; therefore, touch-up injections as well as repeat injections are usually needed to maintain optimal correction. Less material (about half the amount) is usually needed for repeat injections.

**What other treatments are available to me?**

There are a variety of dermal fillers available in the United States that may be used for treatment. Aside from these, additional options for the correction of lines and wrinkles do exist, including facial creams, BOTOX® Cosmetic (onabotulinumtoxinA), chemical peels, and laser skin surface treatments. You may discuss these treatments with your physician.

**When should I notify my physician?**

Be sure to report to your physician (1) any redness and/or visible swelling that lasts for more than a few days and (2) any other symptoms that cause you concern. You may also contact the Allergan Product Support line at 1-877-345-5372.

**For further questions and information, please call Allergan at 1-877-345-5372.**



©2010 Allergan, Inc. \*and™ marks owned by Allergan, Inc. JUVÉDERM® mark owned by Allergan Industrie, SAS. www.juvederm.com Re-order: LDOC-02995-02 104489